Long a frontrunner in donor-derived cell therapy research, Cellectis has announced a strategic pivot away from CAR-T therapies, opting instead to focus on ‘in vivo’ gene editing technologies. This decision comes amid a rapidly evolving landscape in the biotech sector, characterized by increasing competition and regulatory challenges in the CAR-T space. Cellectis’ move to offload its lead programs reflects a broader trend where companies are reassessing their portfolios to align with emerging scientific advancements and market demands.
The implications of this shift are significant for the industry, as Cellectis aims to leverage its expertise in gene editing to explore new therapeutic avenues. This transition not only underscores the need for adaptability in the face of changing market dynamics but also highlights the growing interest in gene editing as a viable alternative to traditional cell therapies. As Cellectis embarks on this new path, stakeholders across the pharma landscape will be closely monitoring its progress and the potential impact on future treatment paradigms.
Use the database as your supply chain compass →
